American College of Cardiology 71st Scientific Sessions: Science Preview, April 3, 2022
At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.
Late-breaking ACC science on Sunday, April 2, begins at a session jointly sponsored by the ACC and the Journal of the American Medical Association, followed by the joint ACC/New England Journal of Medicine session and a second day of featured clinical research.
Look for studies on icosapent ethyl, vupanorsen, and alirocumab for hypercholesterolemia; for landmark research on HFrEF and on a novel FX1a inhibitor for treatment of atrial fibrillation.
Saturday, April 2, 2022 Late Breaking Clincial Trials
Monday, April 4, 2022 Late Breaking Clinical Trials
More News from ACC on Patient Care
Recent Videos
Related Content
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16th 2025Article
The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
